Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class II · Moderate risk

Ramipril Capsules USP

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ongoing Impurity / degradation Hikma Pharmaceuticals USA INC. NDC 76282-673-01 D-0831-2026
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class II · Moderate risk

Enalapril Maleate Tablets

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

Ongoing Impurity / degradation JB Chemicals and Pharmaceuticals Ltd NDC 64980-688-10 D-0520-2026
Class II · Moderate risk

Metoprolol Tartrate Tablets

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Ongoing Nitrosamine impurity Westminster Pharmaceuticals LLC NDC 69367-355-10 D-0582-2025
Class II · Moderate risk

Metoprolol Tartrate Tablets

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Ongoing Nitrosamine impurity Westminster Pharmaceuticals LLC NDC 69367-354-10 D-0581-2025
Class II · Moderate risk

Metoprolol Succinate Extended-Release Tablets

Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.

Ongoing Dissolution failure Granules Pharmaceuticals Inc. NDC 70010-780-01 D-0510-2025
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025
Class II · Moderate risk

Lisinopril Tablets

Presence of Foreign Object: A pharmacist discovered a metal fragment embedded in a lisinopril 10 mg tablet.

Terminated Particulate / foreign matter Evaric Pharmaceuticals Inc. NDC 68645-610-90 D-0061-2025
Class II · Moderate risk

Ramipril Capsules USP 10 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-591-09 D-0054-2025
Class II · Moderate risk

Ramipril Capsules USP 5 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-590-09 D-0053-2025
Class II · Moderate risk

Ramipril Capsules USP 2.5 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-589-09 D-0052-2025